drugset / Trial / NCT01022801
A Phase II Dose Response Study in Japan in Chronic Hepatitis B
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To demonstrate the dose response of entecavir in Japanese patients as measured by HBV DNA levels by PCR (log10 copies/mL) at Week 22
Timeline
- Start
- 2003-08
- Primary completion
- 2005-03
- Completion
- 2005-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entecavir | Small molecule | 0.01 mg | Oral |
| Subject | Entecavir | Small molecule | 0.1 mg | Oral |
| Subject | Entecavir | Small molecule | 0.5 mg | Oral |